102 unknown, 87 completed, 81 recruiting, 34 not yet recruiting. 353 Phase 2, 41 Phase 1, 15 Phase 3.
Follow Esophageal Squamous Cell Carcinoma: new trials by email Literature Review of Esophageal Squamous Cell Carcinoma trials Research Report on Esophageal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma Sacituzumab tirumotecan, Toripalimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 33 | 2026-10-01 | 2026-09-16 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-26 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-10-26 |
| Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes Anlotinib, Anti-PD-1 Monoclonal Antibody - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 75 | 2026-09-01 | 2026-09-21 |
| Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 32 | 2026-09-01 | 2026-09-02 |
| Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma Sacituzumab Tirumotecan + Tagitanlimab - ESCC, Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 75 | 2026-08-31 | 2026-07-14 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma SKB500, Tislelizumab, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 120 | 2026-08-13 | 2026-10-20 |
| Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer Ipilimumab (1mg/kg), Sinitilimab, Nab-paclitaxel + Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-sen University | 51 | 2026-08-01 | 2026-08-07 |
| Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II Becotatug Vedotin, Tislelizumab, Lenvatinib - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 36 | 2026-08-01 | 2026-07-16 |
| Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC Adebrelimab, Nab paclitaxel, Carboplatin - Esophageal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-07-31 | 2026-07-29 |
| Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer Sacituzumab Tirumotecan (SKB264) plus Tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Shanghai Chest Hospital | 28 | 2026-07-30 | 2026-09-10 |
| Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 110 | 2026-07-14 | 2026-07-22 |
| Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Albumin-bound paclitaxel, Low-dose Short-course Radiotherapy, High-dose Short-course Radiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Not yet recruiting | Tang-Du Hospital | 50 | 2026-07-10 | 2026-07-01 |
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor, Retlirafusp alfa / Indole-3-carbinol + Black garlic fermentation extract / Lactobacillus rhamnosus / Placebo + Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor - Valid MeSH Conditions | Phase 2 | Not yet recruiting | Sun Yat-sen University | 347 | 2026-07-07 | 2026-07-16 |
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 140 | 2026-07-01 | 2026-07-17 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
Showing 20 of 353. Sign in to see all of them.
Esophageal Neoplasms (92) · Adenocarcinoma Of Esophagus (53) · Squamous Cell Carcinoma of Head and Neck (21) · Stomach Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (14) · Carcinoma, Squamous Cell (10) · Uterine Cervical Neoplasms (8) · Colorectal Neoplasms (7) · Melanoma (6) · Neoplasm Metastasis (6) · Parkinson Disease 4, Autosomal Dominant Lewy Body (6) · Small Cell Lung Carcinoma (6) · Esophageal Diseases (5) · Neoplasms (5)
Neoplasms, Glandular and Epithelial (353) · Digestive System Diseases (352) · Gastrointestinal Diseases (352) · Neoplasms by Histologic Type (352) · Neoplasms by Site (352) · Carcinoma (351) · Digestive System Neoplasms (351) · Gastrointestinal Neoplasms (351) · Neoplasms, Squamous Cell (351) · Head and Neck Neoplasms (349) · Esophageal Diseases (348) · Neoplasms (348) · Carcinoma, Squamous Cell (343) · Esophageal Neoplasms (261) · Bronchial Neoplasms (15)
Cisplatin (86) · Paclitaxel (59) · Radiotherapy (54) · Fluorouracil (41) · Carboplatin (40) · Drug Therapy (26) · pembrolizumab (24) · tislelizumab (22) · toripalimab (19) · Irinotecan (18) · Oxaliplatin (17) · camrelizumab (16) · 130-nm albumin-bound paclitaxel (15) · Neoadjuvant Therapy (15) · Capecitabine (13)
Sun Yat-sen University (19) · Fudan University (17) · Peking University (13) · The First Affiliated Hospital of Zhengzhou University (12) · Shanghai Chest Hospital (9) · Tianjin Medical University Cancer Institute and Hospital (9) · Zhejiang Cancer Hospital (8) · Hebei Medical University Fourth Hospital (7) · Memorial Sloan Kettering Cancer Center (7) · National Taiwan University Hospital (6) · Second Affiliated Hospital, Zhejiang University, School of Medicine (6) · Shanghai Zhongshan Hospital (6) · Tang-Du Hospital (6) · Samsung Medical Center (5) · Sichuan Cancer Hospital and Research Institute (5)
China (218) · United States (68) · South Korea (24) · Taiwan (21) · France (16) · Italy (10) · Japan (9) · Germany (8) · Spain (8) · Brazil (7) · Singapore (7) · Switzerland (7) · Thailand (7) · United Kingdom (7) · Belgium (5)
David H. Ilson, MD, PhD (5) · Hui Liu, Professor (4) · Lin Shen, MD (4) · Feng Wang (3) · Mian Xi, MD (3) · Qiong Zhao, MD (3) · Thomas Ruhstaller, MD (3) · Aminah Jatoi, MD (2) · David J. Adelstein, MD (2) · Feng Wang, Doctor (2) · Gary K. Schwartz, MD (2) · Hui Liu, Ph.D (2)
PMID 36990609, PMID 28742685, PMID 41309527, PMID 41531940, PMID 12167786, PMID 14759776, PMID 15533252, PMID 15800321, PMID 16515704, PMID 16601427, PMID 17921712, PMID 18270704, PMID 18574157, PMID 18845990, PMID 19465425, PMID 19738454, PMID 20016233, PMID 20304399, PMID 20502056, PMID 20975604, PMID 21205757, PMID 21464865, PMID 21507583, PMID 21879261, PMID 21892283, PMID 22646630, PMID 24139225, PMID 24419108, PMID 24438695, PMID 24533532, PMID 24556041, PMID 24950987, PMID 25320535, PMID 26784946, PMID 26884585, PMID 27152857, PMID 27244882, PMID 27382098, PMID 27890801, PMID 28314688, PMID 28317872, PMID 28823862, PMID 29933761, PMID 30089078, PMID 30642373, PMID 31236579, PMID 32561664, PMID 32864805, PMID 32883216, PMID 32965635
2016 (2), 2023 (2), P30CA006927 (2), P30CA043703 (2), U10CA032102 (2), 2015 (1), 2017 (1), 2019 (1), I01CX002349 (1), N01CM62204 (1), N01CM62206 (1), P30CA008748 (1), P30CA016056 (1), P30CA033572 (1), U10CA021115 (1)